SCHEMBL832432

SCHEMBL832432

Cc1cc2c(-c3ccc[nH]c3=O)c(C(=O)NS(C)(=O)=O)n(Cc3cc4ccccc4nc3Cl)c2cc1Cl

nearest known ligand 0.69

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
CYP2C8 P10632 1/20 0.69
KMT2A Q03164 8/20 0.37
RCE1 Q9Y256 1/20 0.36
CCR2 P41597 1/20 0.34
MEN1 O00255 2/20 0.34
KDM4E B2RXH2 3/20 0.34
ALDH1A1 P00352 3/20 0.34
SCN9A Q15858 4/20 0.33
FAAH O00519 1/20 0.33
GAA P10253 1/20 0.33
MCL1 Q07820 1/20 0.33
CYP1A2 P05177 1/20 0.33
HPGD P15428 1/20 0.33
CHEK1 O14757 1/20 0.32
CDK1 P06493 1/20 0.32
WEE1 P30291 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL832851 0.92 CYP2C8 (0.66) CYP2C8KMT2ARCE1MEN1KDM4E
SCHEMBL831650 0.91 CYP2C8 (0.65) CYP2C8KMT2ARCE1MEN1KDM4E
SCHEMBL832115 0.90 CYP2C8 (0.62) CYP2C8KMT2ARCE1CCR2MEN1
SCHEMBL12673764 0.89 CYP2C8 (0.86) CYP2C8KMT2ARCE1MEN1KDM4E
SCHEMBL862450 0.88 CYP2C8 (0.60) CYP2C8KMT2ARCE1CCR2MEN1
SCHEMBL832847 0.87 CYP2C8 (0.65) CYP2C8KMT2ARCE1CCR2MEN1
SCHEMBL831987 0.86 CYP2C8 (0.60) CYP2C8KMT2ARCE1MEN1SCN9A
SCHEMBL832172 0.86 CYP2C8 (0.76) CYP2C8KMT2ARCE1MEN1KDM4E
SCHEMBL832518 0.86 CYP2C8 (0.79) CYP2C8KMT2ARCE1CCR2MEN1
SCHEMBL10143822 0.85 CYP2C8 (0.63) CYP2C8KMT2ARCE1CCR2MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8143305-B2 2,3-substituted indole derivatives for treating viral infections SCHERING CORPORATION (US) 2012-03-27 US disclosed
US-8143305-B2 2,3-substituted indole derivatives for treating viral infections SCHERING CORPORATION (US) 2012-03-27 US disclosed
US-20110033417-A1 2,3-SUBSTITUTED INDOLE DERIVATIVES FOR TREATING VIRAL INFECTIONS MERCK SHARP & DOHME CORP. 2011-02-10 US disclosed
US-20110033417-A1 2,3-SUBSTITUTED INDOLE DERIVATIVES FOR TREATING VIRAL INFECTIONS MERCK SHARP & DOHME CORP. 2011-02-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110033417-A1 2,3-SUBSTITUTED INDOLE DERIVATIVES FOR TREATING VIRAL INFECTIONS IDO2, IDO1, IRF3 CYP2C8 847/4885KMT2A 321/4885RCE1 1745/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.